Rajan, P., Frew, J. A., Wilson, J. M., Azzabi, A. S.T., McMenemin, R. M., Stockley, J., Soomro, N. A., Durkan, G., Pedley, I. D. and Leung, H. Y. (2015) Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non–castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 33(8), 337.e1-337.e6. (doi: 10.1016/j.urolonc.2015.05.012) (PMID:26092557)
Full text not currently available from Enlighten.
Abstract
Background and objective: Sequential tissue biopsies taken during clinical trials of novel systemic anticancer therapies for advanced prostate cancer (PCa) may aid pharmacodynamic evaluation and biomarker discovery. We conducted a single institution phase-II open-labeled randomized study to assess the safety, tolerability, and early efficacy of docetaxel chemotherapy plus androgen deprivation therapy (ADT) vs. ADT alone for patients with advanced non–castration-resistant PCa with sequential prostatic biopsies. Patients and methods: We randomized 30 patients with newly diagnosed high-grade locally advanced or metastatic (cT3–4/N0–1/M0–1) PCa to receive ADT with (n = 15) or without (n = 15) docetaxel. Transrectal ultrasound–guided prostatic biopsies were taken at randomization and ~22 weeks after treatment initiation. Primary end point: biochemical response rate. Secondary end points: time to progression and tumor profiling. Results: Both treatments appear to be well tolerated, and there was no difference in mean nadir prostate-specific antigen and time to prostate-specific antigen relapse between treatment arms (P>0.05). No adverse effects of pre- and post-treatment prostatic biopsies were observed. The study was neither designed nor sufficiently powered to demonstrate statistically significant differences in oncological outcomes or safety profiles between the 2 treatment arms. Conclusions: Despite the lack of statistical power, our study suggests that docetaxel and ADT in combination may be well tolerated with apparently similar short-term efficacy compared with ADT alone for high-grade locally advanced or metastatic non–castration-resistant PCa, Sequential prostatic biopsies may provide tissue for tumor profiling to yield mechanistic or prognostic insights relating to novel systemic anticancer therapies.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Leung, Professor Hing |
Authors: | Rajan, P., Frew, J. A., Wilson, J. M., Azzabi, A. S.T., McMenemin, R. M., Stockley, J., Soomro, N. A., Durkan, G., Pedley, I. D., and Leung, H. Y. |
College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences |
Journal Name: | Urologic Oncology: Seminars and Original Investigations |
Publisher: | Elsevier |
ISSN: | 1078-1439 |
ISSN (Online): | 1078-1439 |
Published Online: | 16 June 2015 |
University Staff: Request a correction | Enlighten Editors: Update this record